Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. - Wikidata - wikimedia - TriplyDB

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

http://www.wikidata.org/entity/Q34632818

about

Patient-derived tumour xenografts as models for oncology drug development Recent progress in pancreatic cancer Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan Molecular therapeutics in pancreas cancer The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts Adjuvant therapy for pancreas cancer in an era of value based cancer care Genomic alterations in pancreatic cancer and their relevance to therapy Perspectives in the treatment of pancreatic adenocarcinoma Albumin-bound paclitaxel in solid tumors: clinical development and future directions Neoadjuvant therapy for localized pancreatic cancer: guiding principles Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction Advances in systemic therapy for advanced pancreatobiliary malignancies Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Desmoplasia and chemoresistance in pancreatic cancer Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications Alternative fuels for cancer cells Genetically engineered mouse models of pancreatic adenocarcinoma Inflammatory networks and immune surveillance of pancreatic carcinoma Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice One mouse, one patient paradigm: New avatars of personalized cancer therapy The pancreas cancer microenvironment Exploiting inflammation for therapeutic gain in pancreatic cancer SIBLINGs and SPARC families: their emerging roles in pancreatic cancer Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Genetic factors affecting patient responses to pancreatic cancer treatment FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer Dilemma of first line regimens in metastatic pancreatic adenocarcinoma Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma New challenges in perioperative management of pancreatic cancer Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

P2860

Q24604068-903AEACA-779C-44D6-B9B7-64359B6F35F6 Q24626346-F9C0368C-B176-4EA8-BB91-5428EB10B4FE Q24627664-B41BD56B-BB3B-4AA2-AC35-6CBABA81CE4D Q24630174-B73621D3-AC03-412F-8B26-533049AB9D8D Q26740619-FE43EECB-EC7A-402E-8016-8E35606DD634 Q26751368-EC2DEFB7-7949-4F78-9846-BCC5BEA1061B Q26751709-51ADBA1F-E9F5-4A85-BA49-FFB950573F09 Q26765247-F02C44FE-9A97-4376-96B8-2D7F2736CF39 Q26767120-F2CE341A-F446-4715-81A5-5B2E7BAEDEF4 Q26770931-D6374DD0-9AE5-45BF-AEC2-1BE8C99EE04E Q26772895-E62CDDF9-2CC0-4579-96BF-F5C4EBE1DC90 Q26775916-254953EC-299C-4C14-943F-0D50C63E5E05 Q26781443-39941E79-1F23-4BE8-BEFC-EECF8C3CEC1F Q26797248-9EC9D7A9-9585-46EE-AE9E-5CE808CA039F Q26798674-1041824D-B1C2-4D37-9B26-A9E7998DC75A Q26799428-B4609CE6-DED2-4F1D-9EFD-AA35444766A0 Q26799714-504FEF2F-4430-433D-BCFC-ECB6509641FF Q26801834-E7411B15-6C49-4C71-B963-B65431407939 Q26822703-6259B3CE-ACD2-48E8-ABE8-2F4D5944E91F Q26827392-220CEE72-BDAB-445E-A3E8-A8162AD5AAC2 Q26830913-6A8EE62B-F7F9-4CA3-88BD-43B4CAFA9A6C Q26864497-F6F1C482-3DAC-4564-A20C-14B9CF5EEA14 Q26996400-8CDDA38A-8246-493D-BBF0-3F6EEDC53DD9 Q26997591-83281212-BC74-49E2-9F5A-1D9E752A9386 Q27002973-78B3BA2A-83BE-4DB4-83B6-DA39BAAE0B8C Q27013983-6E318801-1E8E-4AA6-B1D3-8607D74CAD35 Q27015651-D61F7503-C68A-4026-B655-7E0F9DDECE81 Q27023342-39E01F1C-51C4-4C80-ADBF-E0A48813DFD7 Q27026705-8C6B3C78-9B35-4F0C-B131-F107ED3A84B2 Q27027661-53B32F9F-1C31-4385-AA84-233B9EB6B3FA Q27027759-92176CCB-56E9-4447-837A-10F4D6CAE3F6 Q27308683-5FF74123-A39C-4ED4-B172-BED770170B7F Q27336445-29B56227-7F1E-427D-B712-3A825F51160E Q28066268-E42DC178-D4F3-456D-A457-E72A8421405C Q28075293-0E3B8893-3010-46C5-AEEA-0A7B7136796D Q28075540-769C196B-0BA7-46DB-8F93-EBC5F99FF19E Q28077147-5D31A95D-4B7B-46E0-913E-0647DCF0449C Q28077206-9245FA8B-98AA-4466-B199-141D628EF793 Q28082422-ACAF2A97-EC77-48F9-BB53-0083187B183B Q28082919-64EFC980-C655-4FFA-8CDE-76084E84FD5A

P2860

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

http://www.wikidata.org/entity/Q34632818

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@ast

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@en

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@nl

type

label

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@ast

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@en

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@nl

prefLabel

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@ast

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@en

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@nl

P1433

Q34632818-0DD53C95-085B-43B6-AEDB-F70391B955E3

P1476

Q34632818-7F0698FA-9D6C-4D0A-9D06-C5E0155D673F

P2093

Q34632818-05B03F2E-EC3E-4C4D-AD75-781528B6BDAC

Q34632818-09F807A0-958D-4CC7-91E7-DFCFA818E772

Q34632818-13AD7308-7A53-4AB9-AD47-AF76CB58F264

Q34632818-6EE976E8-846D-44CF-AC64-2E0EB3246AD0

Q34632818-8C1838D4-C037-476E-B932-EF1DFA86CF2A

Q34632818-B308C37B-5930-4B79-A4C7-323B7B6E5238

Q34632818-BA0457C7-3400-4542-9E31-D6FDE4408DDB

Q34632818-BEF1C3FD-01AB-42F6-BE03-69E7BDEFF314

Q34632818-C7F7EB51-C2B4-4439-B1B5-5CB2ECF57496

Q34632818-D1ADC667-9510-4575-89E1-959C5FBCD73D

P2860

Q34632818-0B1CEDC9-9055-4724-9B87-DE3D9D8ACA89

Q34632818-0D67323B-A006-44EA-A052-9EBFB53217AE

Q34632818-0D8A3CEC-BC2E-4DD6-8F7D-9CEAEDB7041D

Q34632818-11E723E9-1FE5-4134-B855-AF88643422E3

Q34632818-1E32055C-994F-4491-9AD9-7DF7A5DE6264

Q34632818-21C14B5B-AF22-4274-89A3-21CDC1FDC04A

Q34632818-2394CC2F-8058-41B5-A403-609FDD839D48

Q34632818-4F66FBB3-1D7B-4F30-87A2-2AB3FFAC66BC

Q34632818-615F641E-EA43-4BA0-916D-7972F3751951

Q34632818-6F441576-B2A2-469C-BDF9-9882C563B22F

P304

Q34632818-577F6270-7B50-41A8-BB84-F46827A0714A

P31

Q34632818-336459FF-54E6-4A0D-A444-7C5A636D117D

P356

Q34632818-2BC53C1F-EF30-49B1-9F4D-755D754A2352

P407

Q34632818-67AE5C55-2EE2-4866-AF8C-F952E234595F

P433

Q34632818-5BEF5952-7577-4032-A64F-B1A58E19AF91

P478

Q34632818-8476C198-0C7D-4D04-8B7E-5D2DDFD8C80F

P50

Q34632818-0A9E0172-54B8-4D87-A109-CBBAAEEEE007

P577

Q34632818-2DB9983B-8641-435C-B817-530E695D5A4C

P5875

Q34632818-53CFF5C6-509D-4684-9B3B-E1CB69F031A5

P698

Q34632818-845E2A30-6B07-4AFD-BA20-7CDCD49E95B9

P921

Q34632818-4E931D2D-EC47-4DB5-9179-16759BDBB74F

Q34632818-DD4930A9-F236-429B-ABA1-AA4720072C7D

P932

Q34632818-FA3A6D44-FC17-4219-B9E7-8755BEACF764

P356

JCO.2011.36.5742

P1433

Journal of Clinical Oncology

P1476

Gemcitabine plus nab-paclitaxe ...... ic cancer: a phase I/II trial.

@en

P2093

Anirban Maitra

http://www.w3.org/2001/XMLSchema#string

Daniel A Laheru

http://www.w3.org/2001/XMLSchema#string

Daniel D Von Hoff

http://www.w3.org/2001/XMLSchema#string

Hui Zhang

http://www.w3.org/2001/XMLSchema#string

Jose L Iglesias

http://www.w3.org/2001/XMLSchema#string

Lon S Smith

http://www.w3.org/2001/XMLSchema#string

Mitesh J Borad

http://www.w3.org/2001/XMLSchema#string

N V Rajeshkumar

http://www.w3.org/2001/XMLSchema#string

Neil Desai

http://www.w3.org/2001/XMLSchema#string

Patrick Soon-Shiong

http://www.w3.org/2001/XMLSchema#string

P2860

Osteonectin influences growth and invasion of pancreatic cancer cells

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Pancreatic cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.

P304

4548-4554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.36.5742

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51691178

http://www.w3.org/2001/XMLSchema#string

P698

21969517

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

P932

3565012

http://www.w3.org/2001/XMLSchema#string